Acotec Scientific FY26 H1 swings to net loss of RMB 80.83 million; revenue falls 5.6% to RMB 331.58 millionPUBT·Aug 31 at 11:21 AM06669-0.26%
Capital Reallocation in Hong Kong’s Mid-Cap Space: From Global M&A to Defensive ConsolidationGlobal Report·Aug 18 at 10:12 AM01969-0.53%023120.00%
Acotec Scientific expects H1 net loss up to RMB 80.9 million, swings from profitPUBT·Aug 12 at 10:27 AM06669-0.26%
HK Niche Sectors Shift: Tiangong Enters Robotics, Acotec Explores AIGlobal Report·Jul 22 at 09:18 AM06669-0.26%81810+3.19%
20:30 ETWiwynn Advances Datacenter Design at Computex 2026 with High-Power and Optical Interconnectprnewswire·May 26 at 12:30 AM06669-0.26%
"Performance" ACOTEC's annual net profit is 119 million RMB, up 128%, no dividend declaredAASTOCKS·Mar 26 at 09:05 AM516930+2.32%159837+2.74%
Morning Trend | ACOTEC-B continues to be sluggish, with a strong atmosphere of wait-and-see among major playersTechnical Forecast·Jan 16 at 01:00 AM06669-0.26%
Acotec Scientific to Hold EGM for Key Agreement ApprovalsTip Ranks·Dec 16, 2025 at 10:52 PM06669-0.26%
SDIC Securities Sticks to Their Buy Rating for Acotec Scientific Holdings Limited (7W3)Tip Ranks·Nov 27, 2025 at 05:06 AM06669-0.26%
ACOTEC-B: The intravascular radiofrequency ablation system has obtained 510(K) market access approval from the U.S. Food and Drug AdministrationZhitong·Oct 9, 2025 at 09:16 AM06669-0.26%
